BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

ENANTA PHARMACEUTICALS — Lobbying — Receipts Report

LD-2 disclosure · 2nd Quarter - Report

ENANTA PHARMACEUTICALS

via SLAIMAN CONSULTING LLC

2nd Quarter (Apr 1 - June 30) · 2024Posted Jul 2, 2024Filing document ↗LDA record ↗

Coverage · No income or expenses were reported on this filing.

Client

Name: ENANTA PHARMACEUTICALS
Description: clinical stage biotechnology
Location: Massachusetts · United States of America

Registrant

Firm: SLAIMAN CONSULTING LLC
Description: consulting firm
Location: McLean, Virginia, United States of America

Lobbying activities

1 issue

Health Issues
Covid policies
LobbyistsGARY SLAIMAN
TargetedSENATE

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.